Eltrombopag

證據等級: L5

預測適應症: 1 個

Eltrombopag: From Thrombocytopenia to HIV Infectious Disease

One-Sentence Summary

Eltrombopag is a thrombopoietin (TPO) receptor agonist historically used to raise platelet counts in thrombocytopenic disorders (e.g., immune thrombocytopenia, aplastic anemia, hepatitis C-associated thrombocytopenia). The TxGNN model predicts it may also be relevant to HIV infectious disease, with 5 clinical trials and 10 publications currently available as supporting context — though none of the trials directly target HIV as the primary indication, and the evidence is largely indirect (comorbidity-based).

Quick Overview

Item	Content
Original Indication	Not available in formal registry data; pharmacologically known as a treatment for thrombocytopenic disorders (ITP, aplastic anemia, HCV-related thrombocytopenia)
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.26%
Evidence Level	L4
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap). Based on known pharmacology, eltrombopag is a small-molecule TPO receptor (MPL) agonist that stimulates megakaryocyte production to raise platelet counts. Its established uses are all in thrombocytopenic disorders — it is not classified as an antiretroviral or antiviral agent.

The connection to HIV infectious disease appears to arise from two distinct pathways, and it is important not to conflate them. First, a comorbidity pathway: HIV infection and its treatment are frequently associated with immune thrombocytopenia (ITP) and immune reconstitution inflammatory syndrome (IRIS)-related thrombocytopenia. Multiple case reports and a case series in the literature describe eltrombopag being used successfully off-label to manage HIV-associated ITP and aplastic anemia, including one report noting a possible immunomodulatory effect (reduced Th1/Th17 proinflammatory T-helper populations). Second, an independent mechanistic hypothesis: a single in-vitro drug-repurposing screen (PMID 32977702) identified eltrombopag as a modulator of HIV-1 proviral transcription, possibly related to its zinc-finger-binding chemistry — but this finding has not been validated in cell-infection models or clinical studies.

Taken together, the TxGNN high score most likely reflects the knowledge graph's strong "HIV – thrombocytopenia – eltrombopag" co-occurrence pattern rather than a direct, validated antiviral mechanism. Readers should clearly distinguish between "treating HIV-associated thrombocytopenia" (reasonably well supported) and "treating HIV infection itself" (speculative, preclinical only).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00996216	Phase 3	Completed	27	Rollover safety/tolerability study of eltrombopag for maintaining platelet counts in HCV-related thrombocytopenia; not HIV-specific
NCT00529568	Phase 3	Completed	759	RCT evaluating eltrombopag's ability to enable HCV antiviral therapy initiation via sustained virologic response; not HIV-specific
NCT00678587	Phase 3	Terminated	292	RCT assessing eltrombopag to reduce platelet transfusion needs in chronic liver disease patients undergoing invasive procedures; trial terminated, not HIV-specific
NCT00516321	Phase 3	Completed	687	RCT assessing eltrombopag for maintaining platelet counts to enable HCV antiviral therapy (SVR endpoint); not HIV-specific
NCT01636778	Phase 2	Completed	45	Open-label study of eltrombopag (research code SB-497115-GR) raising platelet counts in HCV-related compensated cirrhosis; not HIV-specific

Note: None of the above trials enrolled HIV patients or used HIV-related endpoints. All five support eltrombopag's established efficacy in thrombocytopenia associated with hepatitis C/chronic liver disease; TxGNN links this evidence to HIV via the shared "thrombocytopenia" comorbidity node rather than a direct HIV trial.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19932434	2009	Review	Hematology/Oncology Clinics of North America	Chronic HCV, HIV, and H. pylori infections are recognized causes of secondary immune thrombocytopenia; treating the underlying infection often improves platelet counts
19245929	2009	Review	Seminars in Hematology	Discusses therapeutic strategies for infection-related immune thrombocytopenia, including HCV and HIV as recognized secondary causes
24816314	2014	Review	Internal Medicine Journal	Reviews thrombopoietin receptor agonist use in immune thrombocytopenia of less than 6 months' duration
32977702	2020	Preclinical/In-vitro Screening	Viruses	Drug-repurposing screen of FDA-approved compounds identifies eltrombopag as a modulator of HIV-1 proviral transcription; in-vitro only, no infection-model or clinical validation
22185370	2012	Cohort	Platelets	Danish cohort of TPO-receptor agonist use in refractory ITP, including secondary ITP cases (e.g., chronic lymphocytic leukemia); real-world off-label use patterns
25504472	2015	Case Series	Journal of the International Association of Providers of AIDS Care	Case series on TPO receptor agonists (eltrombopag, romiplostim) as salvage therapy for refractory HIV-associated immune thrombocytopenic purpura
22992580	2012	Case Report	AIDS	Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia
25333665	2014	Case Report	AIDS	First reported successful treatment of HIV-associated severe aplastic anemia with eltrombopag, with evidence of an immunomodulatory effect (reduced Th1/Th17 cells)
28043314	2016	Case Report	Journal of the College of Physicians and Surgeons Pakistan	Case of hepatitis B (not HIV) leading to megaloblastic anemia and severe thrombocytopenia; included as a related infection-thrombocytopenia case
24128106	2013	Case Report	Farmacia Hospitalaria	Two case reports of eltrombopag used for thrombocytopenia in chronic hepatitis C patients

Germany Market Information

No marketing authorizations are currently on file for eltrombopag in this market (0 licenses recorded; market status: Not Marketed).

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug-drug interaction data could not be retrieved for eltrombopag in this evaluation (see Data Gap DG001, classified as Blocking — this currently prevents progression to the S1 safety pre-assessment stage).

Conclusion and Next Steps

Decision: Hold

Rationale: The HIV infectious disease prediction is currently supported only by indirect, comorbidity-based evidence (case reports/case series of eltrombopag treating HIV-associated thrombocytopenia) and a single unvalidated in-vitro screening finding on HIV-1 proviral transcription — no trial has evaluated eltrombopag against HIV infection itself. Combined with a blocking data gap in safety/label information and the absence of any market authorization, the evidence base is not yet sufficient to advance past the research-question stage.

To proceed, the following is needed:

TFDA/package insert warnings and contraindications (Data Gap DG001 — currently blocking S1 safety pre-assessment)
Confirmed mechanism of action data from DrugBank or equivalent source (Data Gap DG002)
Cell-infection-model (not just in-vitro screen) validation of the HIV-1 proviral transcription modulation reported in PMID 32977702
A clearly scoped clinical study (or at minimum a retrospective cohort) evaluating antiviral/virologic outcomes in HIV patients, distinct from existing thrombocytopenia-support evidence
Regulatory pathway and market authorization assessment before any local development decision
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.